The Gut Microbiome–Endocrine Axis in Obesity: Mechanisms and Therapeutics
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70511 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Hongfeng Mao und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Shanghai Key Laboratory of Diabetes Mellitus, Depa…. Hauptthemen laut MEDLINE: Obesity, Gastrointestinal Microbiome, Endocrine System. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shenzhen Medical Research Fund, Major Research Plan of National Natural Science Fund of China (NSFC), Excellent Young Scientists Fund of the National Natural Science Foundation of China (Overseas).
Abstract (Originalsprache)
Obesity, a major global health challenge and a key risk factor for metabolic diseases, represents a state of dysregulated energy homeostasis. The gut microbiome has emerged as a critical mediator of obesity pathogenesis, yet the precise endocrine mechanisms linking microbial signals to metabolic dysfunction remain incompletely understood. Therefore, at the perspectives of gut microbiome–endocrine axis encompassing gut–brain, gut–adipose, and gut–pancreas axes, this review elucidates how gut microbiota and their metabolites influence systemic endocrine homeostasis through energy intake, fat storage, and hormonal secretion. Mechanistic studies highlight the roles of short‐chain fatty acids, bile acids, and microbial peptides in modulating obesity control and related metabolic health. We further summarize the current therapeutics targeting gut microbiome in the gut–endocrine axis, including prebiotics, probiotics, synbiotics, postbiotics, fecal microbiota transplantation, and lifestyle approaches and highlight their mechanistic and translational relevance. The major challenges of gut microbiome studies are discussed, including obscure phenotyping, insufficient cross‐organ integration, and limited causal inference. Overcoming these limitations by precise obesity measurement, integrated cross‐organ models, and AI‐driven causal modeling could advance the pathophysiological insight and management of obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Shanghai Key Laboratory of Diabetes Mellitus, Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, S…
- Department of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
- Institute for Proactive Healthcare, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Yuwei Lu
Förderung
- Shenzhen Medical Research Fund
- Major Research Plan of National Natural Science Fund of China (NSFC)
- Excellent Young Scientists Fund of the National Natural Science Foundation of China (Overseas)
- National Natural Science Foundation of China
Zitieren
APA
Mao, H., Wang, X., Pang, Y., Lu, Y., Wang, H., Li, H., Ni, Y., & Jia, W. (2026). The Gut Microbiome–Endocrine Axis in Obesity: Mechanisms and Therapeutics. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70511
Vancouver
Mao H, Wang X, Pang Y, Lu Y, Wang H, Li H, et al. The Gut Microbiome–Endocrine Axis in Obesity: Mechanisms and Therapeutics. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70511
BibTeX
@article{Mao2026,
author = {Mao, Hongfeng and Wang, Xi and Pang, Yan and Lu, Yuwei and Wang, Hui and Li, Huating and Ni, Yueqiong and Jia, Weiping},
title = {The Gut Microbiome–Endocrine Axis in Obesity: Mechanisms and Therapeutics},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70511}
}
EUVIMED